bullish
Hutchmed China Ltd (13.HK/HCM.US) - 2023 Results Preview and Catalysts in 2024
357 Views20 Feb 2024 08:55
HUTCHMED has entered a harvest period.Product revenue would grow rapidly in the next two years, with promising catalysts head.Together with sufficient cashflow, overall breakeven is achievable in 2025
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (Mar.1) - Prioritize Big Pharma, Real Ownership of Pricing Power, Hengrui03 Mar 2024
- China Healthcare Weekly (Feb.23)- TCM Ushers in a Harvest Period, Biotech Bottom-Line, Kelun-Biotech25 Feb 2024
- China Traditional Chinese Medicine (570.HK) - New Information on Privatization21 Feb 2024
- Hutchmed China Ltd (13.HK/HCM.US) - A Valuable Option in the Portfolio20 Dec 2023
- Hutchmed China Ltd (13.HK/HCM.US) 23H1 - This Company Is Becoming More Attractive07 Aug 2023
- Hutchmed China Ltd (13.HK/HCM.US)- Stronger than Expected and Deserves More Attention from Investors18 May 2023
x